Min (Amy) Xiang

Title: Min (Amy) Xiang: Innovator in Glucokinase Modulation

Introduction

Min (Amy) Xiang, an accomplished inventor based in Bridgewater, NJ, has made significant contributions to the field of pharmacology. With a focus on glucokinase modulation, his work is paving the way for innovative treatments for metabolic disorders, particularly type II diabetes.

Latest Patents

Xiang holds a patent for "Dihydroisoindolones as allosteric modulators of glucokinase." This invention details compounds that serve as glucokinase modulators, offering therapeutic solutions for disorders mediated by glucokinase. The patent provides a comprehensive exploration of the compounds, their preparation methods, and formulations aimed at treating glucokinase-related diseases.

Career Highlights

Currently, Min (Amy) Xiang is employed at Janssen Pharmaceutica NV, a well-regarded pharmaceutical company known for its research and development in innovative therapies. His role is pivotal in advancing the company’s commitment to addressing unmet medical needs through groundbreaking discoveries in drug development.

Collaborations

During his career, Xiang has collaborated with notable colleagues including Hiayan Bian and Joseph Dudash. These partnerships reflect a collaborative spirit that enhances the innovative output of their shared goals and research endeavors.

Conclusion

Min (Amy) Xiang stands out as a forward-thinking inventor whose work on glucokinase modulators holds promise for the treatment of type II diabetes and related disorders. His patent signifies a notable advancement in therapeutic strategies, reinforcing the importance of innovation in the pharmaceutical industry.